

Critical Care

Catherine M. Szyman
Corporate Vice President

60
Years of
Discovery



Edwards

Driving Growth and Leadership with Innovation

We are **pioneering smart monitoring** to benefit more patients and expand leadership

HemoSphere platform builds the foundation for growth and enables our artificial intelligence capabilities

Acumen IQ technology expected to expand adoption in Enhanced Recovery

**Critical Care
Products Benefit
Millions of Patients
per Year**




We are the global leader in hemodynamic monitoring¹





Shifting Trends Favor Smart Patient Monitoring

Trends in patient care and advanced technologies are enabling:


← Shifting care outside of the hospital →




> Impact on Patient Monitoring

-  Less invasive
-  Data-enabled
-  AI technologies
-  Connected

Pioneering Smart Monitoring with AI to Improve Care



HemoSphere Builds Foundation for Growth



Phased rollout to replace legacy platforms

2018 ————— 2019 ————— 2020 ————— 2021 →

Phase I

Advanced Swan-Ganz Catheter
VIGILANCE II REPLACEMENT


Phase II

FloTrac Sensor
Acumen Hypotension Prediction Index (HPI)
EV1000 REPLACEMENT

Phase III

ClearSight HPI
Connectivity Suite
EV1000 REPLACEMENT


HemoSphere Enables Less-Invasive, Smart Monitoring



Acumen IQ Technology Addresses Clinical Challenges

Acumen Hypotension Prediction Index (HPI)

Smart software that alerts clinicians to address potentially developing **low blood pressure events before they occur**




Perioperative low blood pressure is associated with **poor clinical outcomes**^{1,2}

Planned launches in U.S. and Europe on HemoSphere Platform Q1 2019


Acumen Assisted Fluid Management (AFM)

Decision support tool that evaluates optimal range for fluid levels, **reducing variability and improving outcomes**



Insufficient or excessive volume administration is associated with **serious complications**³

Expect to submit for approval on HemoSphere Platform Q4 2019, anticipate launching in U.S. and Europe in 2020



Acumen IQ



Building Evidence to Create Acumen IQ Claims

Hypotension Prediction Index (HPI)

U.S. single center RCT¹ and multi-center pivotal studies

Objectives

- Obtain hypotension reduction claim
- Provide FDA with evidence to expand HPI claims
- Create evidence to develop guidelines and new national quality standard




Assisted Fluid Management (AFM)


U.S. multi-center Investigational Device Exemption (IDE)

Objectives

- Validation of algorithm
- Increase Enhanced Recovery adoption
- Provide FDA with evidence for approval




Enhanced Recovery to Accelerate Segment Growth



1. Third party research and internal estimates 2. Includes pulmonary artery catheters and invasive pressure monitoring products, excludes capital 3. Includes minimally invasive and non-invasive advanced hemodynamic monitoring products, excludes capital

2019 Underlying Global Sales Growth Outlook



*Underlying
Global Critical Care
Estimated Sales Growth*

Tailwinds

- HemoSphere adoption
- Increased utilization in Asia

Headwinds

- Long conversion cycles
- Slow clinical adoption of new technologies

Executive Summary



We are driving growth and leadership by:

- Pioneering smart monitoring to benefit more patients
- Building the foundation with HemoSphere
- Expanding Enhanced Recovery adoption with Acumen IQ

